Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

Authors: Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman

Source: American journal of hematology. 98(1):E15-E19

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100169845339.0x000001&indx=1&recIds=ETOCvdc_100169845339.0x000001

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

Authors: Martin, Thomas ^*, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille, Garg, Mamta, Quach, Hang, Sia, Hanlon, George, Anup, Konstantinova, Tatiana, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, van de Velde, Helgi, Moreau, Philippe

Source: In Blood Advances 9 August 2022 6(15):4506-4515

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Authors: Moreau, Philippe, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Spicka, Ivan, Baker, Ross, Kihyun, Kim, Martinez, Gracia, Chang-Ki, Min, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Youngil, Koh, Suzuki, Kenshi, Martin, Tom, Quach, Hang, Lim, Andrew, Crowther, Helen, Sia, Hanlon, Hulin, Cyrille, Mohty, Mohamad, Mikala, Gabor, Nagy, Zsolt, Reinoso Segura, Marta, Rosinol, Laura, Yagci, Munci, Turgut, Mehmet, Garg, Mamta, Parmar, Gurdeep, Augustson, Brad, Castro, Nelson, Crusoe, Edvan, Pika, Tomas, Delimpasi, Sosana, Ishizawa, Kenichi, George, Anup, Konstantinova, Tatiana, De La Rubia, Javier, Sung-Hyun, Kim, Maiolino, Angelo, Reiman, Anthony, LeBlanc, Richard, Ito, Shigeki, Tanaka, Junji, Luchinin, Alexander, Kryuchkova, Irina, Martinez, Joaquin, Shustik, Jesse, Karlin, Lionel, Symeonidis, Anargyros, Egyed, Miklos, Petrini, Mario, Cavo, Michele, Uchiyama, Michihiro, Blacklock, Hilary, Arat, Mutlu, Griffin, James, Hunter, Hannah, Buck, Tonda, Anagnostopoulos, Achilles, Konstantopoulos, Konstantinos, Masszi, Tamas, Bringhen, Sara, Gamberi, Barbara, Kawano, Yawara, Jin Seok, Kim, Ozdogu, Hakan, Ozkalemkas, Fahir, Špička, Ivan, Kim, Kihyun, Min, Chang-Ki, Koh, Youngil, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, Martin, Thomas ^*

Source: In The Lancet 19-25 June 2021 397(10292):2361-2371

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Authors: Farnier, Michel, Colhoun, Helen M., Sasiela, William J., Edelberg, Jay M., Asset, Gaëlle, Robinson, Jennifer G.

Source: In Journal of Clinical Lipidology July-August 2017 11(4):986-997

P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis

Authors: Špička, Ivan, Moreau, Philippe, Martin, Thomas, Facon, Thierry, Martinez, Gracia, Oriol, A, Koh, Youngil, Lim, Andrew, Mikala, Gábor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Risse, Marie-Laure, Asset, Gaëlle, Macé, Sandrine, van de Velde, Helgi, Yong, Kwee

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2021 21 Supplement 2:S159-S159

MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis

Authors: Facon, Thierry, Moreau, Philippe, Martin, Thomas G., Spicka, Ivan, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Yong, Kwee, Risse, Marie-Laure, Asset, Gaëlle, Schwab, Sandrine, Martinez, Gracia

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2021 21 Supplement 1:S420-S420

Poster: MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis

Authors: Facon, Thierry, Moreau, Philippe, Martin, Thomas G., Spicka, Ivan, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Yong, Kwee, Risse, Marie-Laure, Asset, Gaëlle, Schwab, Sandrine, Martinez, Gracia

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2021 21 Supplement 1:S250-S250

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Authors: Martin, Thomas, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille ^*, Garg, Mamta ^*, Quach, Hang, Sia, Hanlon ^*, George, Anup ^*, Konstantinova, Tatiana ^*, Risse, Marie-Laure ^*, Asset, Gaelle ^*, Macé, Sandrine ^*, van de Velde, Helgi, Moreau, Philippe ^*

Source: In Blood 5 November 2020 136 Supplement 1:7-8

THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469)

Authors: Roth, Eli M., McKenney, James, Hanotin, Corinne, Asset, Gaelle, Stein, Evan

Source: Journal of the American College of Cardiology. 59(13):E1620-E1620

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100053970779.0x000001&indx=1&recIds=ETOCvdc_100053970779.0x000001

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.